All Life Sciences & Technology News
Top stories summarized by our editors
5/25/2018

Mentoring summer interns at Pfizer has "turned out to be a robust two-way street," writes Sally Susman, Pfizer's executive vice president of corporate affairs. Interns bring optimism, fresh perspectives, energy and humor that refresh the workplace, Susman writes.

Full Story:
Forbes
More Summaries:
Sally Susman, Pfizer
5/25/2018

Although gender and race diversity are important, cognitive diversity, which includes differences in information processing styles and perspectives, is also critical to businesses, writes Heidi Jannenga, co-founder and president of WebPT. When people with diverse knowledge come together, they adapt to change faster, learn faster, overcome challenges more effectively and overcome other social blockers that limit business success.

Full Story:
Entrepreneur online
More Summaries:
Heidi Jannenga
5/25/2018

Using RNA sequencing, Duke University investigators found that the channel protein aquaporin-3 is produced in great quantities once the Plasmodium parasite takes up residence in the liver prior to entering the bloodstream, according to findings published in the journal PLOS Pathogens. Inhibiting the AQP3 protein was linked with reductions in levels of the parasites.

More Summaries:
Malaria, Duke University
5/25/2018

The investigative Ebola treatment mAb114, which was developed from the antibodies of a patient who survived Ebola in 1995, will be dispatched for testing in the Democratic Republic of Congo, according to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. Congo's health ministry requested access to the passive antibody treatment, and Fauci said the testing must be carried out in coordination with the World Health Organization.

Full Story:
Reuters
5/25/2018

Bio-Manguinhos, a unit of Brazil's Oswaldo Cruz Foundation, and Chembio Diagnostics entered into a commercialization agreement in Brazil for assays for dengue, Zika and chikungunya infections. The two have been collaborating since 2016 on viral tests.

5/25/2018

A 212-patient, late-stage trial found that treatment with Imbruvica, or ibrutinib, plus Gazyva, or obinutuzumab, was associated with longer progression-free survival than chlorambucil plus Gazyva among patients with previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Full Story:
BioCentury
5/25/2018

Stem cell therapy developer Magenta Therapeutics is preparing for an initial public offering that could raise about $100 million to be used to advance its cell therapy candidate MGTA-456 toward a pivotal trial. The candidate is being developed as a therapy for inherited metabolic disorders, and the company is also developing a stem cell mobilization candidate.

Full Story:
Endpoints News
5/24/2018

Over-the-counter teething products that contain benzocaine pose a "serious risk to infants and children" and offer no benefit, according to an FDA warning issued Wednesday. Teething gels, sprays, ointments, solutions and lozenges that contain benzocaine could cause the potentially fatal blood condition methemoglobinemia, the FDA said, and the agency is asking manufacturers to stop marketing the products for pediatric use.

Full Story:
USA Today
More Summaries:
FDA, benzocaine, methemoglobinemia
5/24/2018

A voluntary recall was issued by Merrick Pet Care for certain Merrick Backcountry and Castor & Pollux brand dog treats after a consumer complaint of finding high levels of beef thyroid hormone in one of the products. The recalled products include Merrick Backcountry Great Plains Real Beef Jerky, Real Beef Sausage Cuts and Real Steak Patties, as well as Castor & Pollux Good Buddy Prime Patties Real Beef Recipe and Sausage Cuts Real Beef Recipe, all with best-before dates of 5/1/2017 through 9/1/2019, which were distributed to pet stores and grocery stores across the US and via online retailers.

5/24/2018

Pfizer's tafamidis, which is being developed as a treatment for patients with transthyretin cardiomyopathy, was given breakthrough therapy designation by the FDA.

Full Story:
Seeking Alpha
More Summaries:
Pfizer, FDA